Old Web
English
Sign In
Acemap
>
Paper
>
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
Final Results of a Phase II Biomarker-Driven Study of Ruxolitinib in Relapsed and Refractory T-Cell Lymphoma
2019
Alison J. Moskowitz
Paola Ghione
Eric D. Jacobsen
Jia Ruan
Jonathan H. Schatz
Sarah J. Noor
Patricia L. Myskowski
Helen Hancock
Theresa Davey
Obadi Obadi
Carlissa Onwasigwe
Nivetha Ganesan
Lauren Pomerantz
Christine Jarjies
Priyadarshini Kumar
Allison Sigler
Mark B. Geyer
Ariela Noy
David J. Straus
Travis J. Hollmann
Ahmet Dogan
Natasha Galasso
Giorgio Inghirami
David M. Weinstock
Steven M. Horwitz
Keywords:
Immunology
Biomarker (medicine)
Cancer research
Medicine
Refractory T-Cell Lymphoma
Ruxolitinib
Cytopenia
Oncology
Vindesine
T-cell lymphoma
Neutropenia
Internal medicine
Febrile neutropenia
Lymphoma
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
11
Citations
NaN
KQI
[]